Published on 10 Apr 2024 on GuruFocus.com via Yahoo Finance
Director Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO)
Agios Pharmaceuticals Inc (NASDAQ:AGIO), a biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of cancer and rare genetic diseases, has seen a recent insider transaction according to the latest SEC filings. Director Jacqualyn Fouse sold 7,791 shares of the company on April 10, 2024.Jacqualyn Fouse has been actively trading shares over the past year, with a total of 37,622 shares sold and no shares purchased. The insider's latest transaction involved the sale of 7,791 shares at a price point of $27.55 per share, which affected the insider's holdings in the company.The transaction has contributed to the overall insider selling trend at Agios Pharmaceuticals Inc, with a total of 35 insider sells and no insider buys over the past year. This pattern of insider activity can be visualized in the following insider trend image:
On the valuation front, Agios Pharmaceuticals Inc's shares were trading at $27.55 on the day of the insider's sale, giving the company a market capitalization of $1.682 billion. The stock's price-to-GF-Value ratio stands at 0.35, indicating that the stock is significantly undervalued according to the GF Value. The GF Value of $79.26 is an intrinsic value estimate from GuruFocus, which is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates from Morningstar analysts.For a more detailed understanding of the company's valuation, here is the GF Value image: